Skip to content

Study · Not a test of the peptide alone · 2025

6 results

Dually functionalized dendrimer for stimuli-responsive release of active ingredients into the skin.

Trashi O, Satish N, Trashi I, Hagge LM, Wijesundara YH, Hu C, Herbert FC, Smaldone RA, Gassensmith JJ

Acta biomaterialia18 Dec 2024Cited by 7 (Europe PMC)

PMID39694719 (opens in a new tab)DOI10.1016/j.actbio.2024.12.035 (opens in a new tab)PepBankPUB-39694719
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  1. 01LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneEx vivo tissuePharmacokinetics

    In skin delivery experiments, the functionalized dendrimer released biologically active therapeutics into the dermis for 24 h.

    In plain wordsIn lab tests, the functionalized carrier released active treatments into the deeper skin for 24 h.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    Not applicableControlled dermal release
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Skin and wound

    Measurements

    Release duration
    24 h
    functionalized dendrimer

    Source sentences

    Summary
    Using a fourth-generation polyamidoamine (PAMAM), dendrimer functionalized with poly(2-ethyl-2-oxazoline) and palmitoyl pentapeptide-4, we show a controlled release of biologically active therapeutics into the dermis of the skin for 24 h.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  2. 02LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneEx vivo tissuePharmacokinetics

    In ex vivo skin studies, the nanocarrier delivered cargo to the dermis.

    In plain wordsIn lab tests, the carrier delivered its cargo to the deeper skin.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    Not applicableDermal cargo delivery
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Skin and wound

    Source sentences

    Summary
    Ex vivo studies demonstrate that our nanocarrier system delivers cargo to the dermis and is non-toxic to skin fibroblasts.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  3. 03LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneEx vivo tissuePharmacokinetics

    In skin delivery experiments, the nanocarrier enhanced dermal penetration under skin-specific conditions.

    In plain wordsIn lab tests, the carrier increased penetration into the deeper skin under skin-specific conditions.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreaseEnhanced dermal penetration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Skin and wound

    Source sentences

    Summary
    The nanocarrier enables controlled, stimuli-triggered release under skin-specific conditions (pH 5, 37 °C), enhancing dermal penetration and minimizing release at neutral pH or lower temperatures.
    1 context sentence
    Summary · context
    Ex vivo studies demonstrate that our nanocarrier system delivers cargo to the dermis and is non-toxic to skin fibroblasts.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  4. 04LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cells)Safety outcome

    In skin fibroblasts, the nanocarrier system was non-toxic.

    In plain wordsIn cells, the carrier system was non-toxic to skin fibroblasts.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    Not applicableFibroblast toxicity
    Study

    n: not reported in source

    Skin fibroblasts
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Ex vivo studies demonstrate that our nanocarrier system delivers cargo to the dermis and is non-toxic to skin fibroblasts.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  5. 05LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cells)Efficacy outcome

    In human dermal fibroblasts, the carrier co-delivering retinol and palmitoyl pentapeptide-4 enhanced collagen production beyond individual components.

    In plain wordsIn cells, the carrier with retinol and palmitoyl pentapeptide-4 increased collagen production more than individual components.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreaseCollagen production
    Study

    humann: not reported in source

    Human dermal fibroblasts
    Comparator
    Individual components
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    As a proof of principle, we demonstrate a system that effectively enhances collagen production in human dermal fibroblasts by co-delivering all-trans retinol and palmitoyl pentapeptide-4. Our nanosystem surpasses the effects of individual components.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  6. 06LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cell-free)Pharmacokinetics

    In formulation tests, the nanocarrier enabled controlled release under skin-specific conditions and minimized release at neutral pH or lower temperatures.

    In plain wordsIn lab tests, the carrier enabled controlled release under skin-specific conditions and limited release at neutral pH or lower temperatures.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    MixedStimuli-triggered release
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Skin and wound

    Source sentences

    Summary
    The nanocarrier enables controlled, stimuli-triggered release under skin-specific conditions (pH 5, 37 °C), enhancing dermal penetration and minimizing release at neutral pH or lower temperatures.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.